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Abstract: The diagnosis of astroblastoma is based on a typical histological aspect with 
perivascular distribution of cells sending cytoplasmic extensions to the vessels and vascular 
hyalinization. These criteria are useful for standardizing the identification of the tumor, but, 
in spite of this, there are discrepancies in the literature concerning the age distribution and the 
benign or malignant nature of the tumor. Three cases are discussed in this study: Case 1 was 
a typical high-grade astroblastoma; Case 2 was an oligodendroglioma at the first intervention 
and an oligoastrocytoma at the second intervention with typical perivascular arrangements in 
the astrocytic component; Case 3 was a gemistocytic glioma with malignant features and typi-
cal perivascular arrangements. Genetic analysis showed genetic alterations that are typical of 
gliomas of all malignancy grades. Using the neurosphere assay, neurospheres and adherent cells 
were found to have developed in Case 1, while adherent cells only developed in Case 2, in line 
with the stemness potential of the tumors. The cases are discussed in relation to their diagnostic 
assessment as astroblastoma, and it is hypothesized that the typical perivascular distribution 
of cells may not indicate a separate and unique tumor entity, but may be a peculiarity that can 
be acquired by astrocytic gliomas when an unknown cause from the tumor microenvironment 
influences the relationship between vessels and tumor cells.
Keywords: gliomas, cell lines, histology, genetics
Introduction 
Astroblastoma has been, and still is, an often-discussed tumor entity with affinity to 
ependymoma. Its characteristics have been recognized to be the perivascular arrange-
ment of astrocytic tumor cells with broad processes on the vessel walls and vascular 
hyalinization. Since its first description by Bailey,1 the literature on brain tumor clas-
sification has categorized astroblastoma as follows: as a stage in the process of glioma 
dedifferentiation2 and as an astrocytoma of large cells producing fibers3 or as a rare 
tumor, likely originating from tanycytes or ependymal astrocytes, as shown by electron 
microscopy.4,5 Tumor descriptions in the literature only concern individual cases or 
small collections of cases.4–7
Astroblastoma has been prevailingly regarded as a high-grade neoplasm,8 but, 
in a recent review, 5-year survival rates were found in 95% of cases.9 Therefore, 
it could be more frequently a low-grade tumor.10 As a matter of fact, both benign 
and malignant neoplasia have been described, with or without mitoses, endothelial 
proliferations, and necrosis.11 Astroblastoma has been considered to range between 
astrocytoma and glioblastoma multiforme (GBM).12 The main feature of the tumor is 
represented by both perivascular processes, specifically unipolar cytoplasmic processes 
OncoTargets and Therapy 2015:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
452
Mellai et al
anchoring tumor cells to vessels,13 different from those of 
ependymal pseudorosettes, and vascular hyalinization. In 
recently described cases,14–16 the perivascular arrangement 
of cells and vessel hyalinization have been confirmed as 
typical features of this tumor. The TP53 and isocitrate 
dehydrogenase 1 and 2 (IDH1/2) genes have been found 
to be wild type, and the occurrence of microvilli has been 
ultrastructurally observed.17 The main differential diagnoses 
of astroblastoma are ependymoma and angiocentric glioma. 
Ependymoma can be distinguished because of the lack of 
fibrillarity10 in astroblastoma; with angiocentric glioma, 
the distinction is not clear-cut, because this is an ill-defined 
tumor entity, characterized by perivascular distribution of 
cells not otherwise specified, which is benign and occurring 
in children. At worst, astroblastoma might be regarded as an 
angiocentric glioma.18
Based on the data of 95 patients in the literature, astro-
blastoma location was found to be prevailingly supratentorial 
(87 supratentorial versus 8 infratentorial cases). The tumor 
showed a bimodal age distribution, with one peak in infancy 
and the other one in young adults. On magnetic resonance 
imaging (MRI), it typically appeared as a large, lobulated 
mass.9
From the abovementioned paper, a rather wide range 
of phenotypic characteristics emerged after analysis of the 
literature,9 and this means that astroblastomas are collected 
with different criteria.10 Both the perivascular arrangement 
of cells and hyalinization are the most crucial characteris-
tics, and the only means to recognize the tumor, provided 
that it is a stable and diffuse feature and not a sporadic one. 
As a matter of fact, perivascular formations not otherwise 
specified are not a rare occurrence in gliomas. Herein, we 
will discuss three cases in which the perivascular distri-
bution of astrocytic tumor cells, which are distinct from 
ependymomatous cells, occurred in gliomas with different 
phenotypic contexts.
Materials and methods
Cases
Case 1: 77-year-old woman
Two months before admission to the hospital, the patient 
suffered from an epileptic seizure followed by mental 
confusion. The MRI scan showed a 3 cm left frontal mass 
with a ring of contrast enhancement and a peritumoral 
edema (Figure 1). She was operated on at the Depart-
ment of Neurosurgery, CTO Hospital/Città della Salute 
e della Scienza (Turin, Italy), and the mass was removed. 
The diagnosis was World Health Organization (WHO) 
high-grade astroblastoma. The postsurgical period was 
uneventful, and the patient underwent radiotherapy (RT) 
with a total dose of 60 Gy. Ten months later, the MRI with 
contrast enhancement showed a recurrence in the posterior 
wall of the surgical cavity, and the patient was treated with 
 temozolomide. The patient died 18 months after surgery.
Case 2: 68-year-old woman
The clinical presentation was motor aphasia and the MRI 
revealed a hyperintense mass with calcifications in the left 
basal frontal region. The patient was operated on at the Neu-
rosurgical Unit, University of Turin, and the diagnosis was 
of WHO grade II oligodendroglioma.
Eight months later, the tumor recurred, and the patient 
underwent conventional RT with a total dose of 60 Gy. 
Nine months later, another operation was performed, and 
the diagnosis was of WHO grade III oligoastrocytoma. The 
patient died 29 months from the first diagnosis.
Case 3: 60-year-old man
The patient had been treated for papillary eruothelial car-
cinoma. Two months before intervention, the patient had 
cephalalgia and ideomotor slowdown. On MRI, a right, 
hypointense frontal lesion was discovered. The patient was 
operated on at the Neurosurgical Unit, University of Turin. 
The diagnosis was uncertain between a giant cell GBM and 
Figure 1 T1-weighted contrast enhancement magnetic resonance imaging scan of 
Case 1.
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Table 1 List of primary antibodies used for immunohistochemistry
Antibody Source Dilution Code Manufacturer
Ki-67/MiB-1a Mouse 1:100 M7240 Dako Denmark a/s, Glostrup, Denmark
GFaP Mouse 1:200 M0761 Dako Denmark a/s, Glostrup, Denmark
iDH1ri32H a Mouse 1:20 Dia H09 Dianova international, Lausanne, switzerland
Vimentina Mouse Prediluted 790-2917 Ventana Medical systems inc., Tucson, aZ, Usa
CD34a Mouse Prediluted 790-2927 Ventana Medical systems inc., Tucson, aZ, Usa
CD68a Mouse Prediluted 790-2931 Ventana Medical systems inc., Tucson, aZ, Usa
Note: aHeat-induced epitope retrieval required.
Abbreviations: GFAP, glial fibrillary acidic protein; IDH1, isocitrate dehydrogenase 1.
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a gemistocytic astrocytoma with malignant features. The 
patient underwent conventional RT with a total dose of 60 
Gy over 2 months and two cycles of  temozolomide. He was 
still alive 38 months after surgery.
Pathology
All tumor samples were formalin fixed and paraffin embedded 
(FFPE). From paraffin blocks, 5 µm-thick sections were cut 
and stained with hematoxylin and eosin and Gomori silver 
impregnation for reticulum fibers (Bio-Optica, Milan, Italy). 
 Immunohistochemistry with the primary antibodies listed in 
Table 1 was performed on a Ventana Full BenchMark® XT 
automated immunostainer (Ventana Medical Systems Inc., 
Tucson, AZ, USA). The ultraView™  Universal DAB Detection 
Kit was the revelation system. When indicated, heat-induced 
epitope retrieval was performed in Tris–ethylenediaminetet-
raacetic acid, pH 8 (Ventana Medical System Inc.).
The histological diagnosis was in agreement with WHO 
guidelines.19
Molecular genetics
Genomic DNA (gDNA) from FFPE tumor samples and 
matched cell lines was extracted using the QIAamp DNA 
Mini Kit (Qiagen NV, Venlo, the Netherlands), according 
to the manufacturer’s instructions. Constitutive gDNA 
was isolated from peripheral blood by a salting-out 
procedure.
Molecular genetics analyses were performed, as 
previously published.20–23 Allelic imbalances on the 9p, 
10q, and 17p chromosome arms were assessed by loss of 
heterozygosity (LOH) analysis with microsatellite mark-
ers amplified in multiplex reactions by polymerase chain 
reaction (PCR) with fluorescently labeled primers (Thermo 
Fisher Scientific Inc., Walthman, MA, USA). The 1p/19q 
chromosome status was determined by multiplex ligation-
dependent probe amplification with the SALSA-MLPA 
Kit P088 (lot number 0608; MRC-Holland, Amsterdam, 
the Netherlands). Capillary electrophoresis (CE) was 
performed on an ABI® 3130 Genetic Analyzer (Thermo 
Fisher Scientific Inc.).
The EGFR gene amplification status (GenBank sequence 
NM_005228) was assessed by EGFR co-amplification in 
PCR reaction with INF-γ (GenBank sequence NM_000619) 
as reference housekeeping gene, followed by CE.
Quantitative methylation-specific PCR and fragment 
analysis were used to assess the promoter hypermethylation 
status of both the MGMT (GenBank sequence NM_002412) 
and EMP3 (GenBank sequence NM_001425) genes.
TP53 (exons 2 to 11) (GenBank sequence NM_000546), 
PTEN (exons 1 to 9) (GenBank sequence NM_000314) and 
IDH1 Arg132 (exon 4) (GenBank sequence NM_005896), 
IDH2 Arg172 (exon 4) (GenBank sequence NM_002168), 
and BRAF  Val600 (exon 15) (GenBank sequence 
NM_004333) hot-spot codons were amplified by PCR and 
searched for mutations by Sanger direct sequencing. Cycle 
sequencing was performed using the BigDye® Terminator 
v1.1 Cycle Sequencing Kit (Thermo Fisher Scientific Inc.). 
The analysis software programs used were Sequencing 
Analysis v 5.3.1 and GeneMapper v 4.0 (Thermo Fisher 
Scientific Inc.).
Neurosphere assay
Fragments from fresh surgical tumor samples from Cases 1 
and 2 (first intervention) were minced and put in culture 
for the neurosphere (NS) assay.24 Culture conditions were 
Dulbecco’s Modified Eagle’s Medium (DMEM)/F-12 supple-
mented with 20 ng/mL epidermal growth factor (EGF) and 10 
ng/mL basic fibroblast growth factor (bFGF) for NS devel-
opment and DMEM supplemented with 10% fetal bovine 
serum for adherent cell (AC) development. Cell cultures 
were maintained in a 5% O
2
/CO
2
 atmosphere.
To assess NS multipotency, a differentiation assay was 
carried out by mitogen withdrawal and the addition of 3% 
fetal bovine serum to the culture. NS abilities for self-renewal, 
clonogenicity, and tumorigenicity were assessed as described 
elsewhere.21
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Immunofluorescence
Immunofluorescence on cell lines was performed with the 
primary antibodies listed in Table 2. The secondary antibod-
ies used were Alexa Fluor® 488-conjugated AffiniPure goat 
anti-rabbit IgG and Alexa Fluor® 594-conjugated AffiniPure 
rabbit anti-mouse IgG antibodies (Jackson ImmunoResearch 
Laboratories Inc, West Grove, PA, USA). Cell nuclei were 
stained with 4′,6-diamidino-2′-phenylindole, dihydrochloride 
(DAPI). Images were obtained on a Zeiss Axioskop fluores-
cence microscope (Carl Zeiss Meditec AG, Jena, Germany) 
equipped with an AxioCam5MR5c and coupled to an imaging 
system (AxioVision Release 4.5; Carl Zeiss Meditec AG).
For confocal microscopy of glial fibrillary acidic protein 
(GFAP) and nestin, the secondary antibodies used were Alexa 
Fluor® 555 goat anti-rabbit IgG and Alexa Fluor® 488 goat 
anti-mouse IgG (Thermo Fisher Scientific Inc.), respectively. 
High-resolution multichannel images were obtained on a 
Leica SP8 laser-scanning confocal microscope (Leica Micro-
systems, Wetzlar, Germany).
Results
Pathology
Case 1
The tumor showed a high cell density with slightly poly-
morphic nuclei and mitoses (Figure 2A and B). GFAP- and 
vimentin-positive staining were observed (Figure 2C). 
Cells sent thick and short processes without end feet on 
vessels (Figure 2A and B) with no fibrillary component. 
The perivascular formations were diffuse in the tumor and 
were recognized as different from perivascular pseudoro-
settes of ependymoma. The vessel walls were thickened, 
with mild hyalinization. Microvascular proliferations and 
glomeruli were frequent, especially at the periphery. Large 
and circumscribed necroses with pseudopalisading were 
present (Figure 2B). The Ki-67/MIB-1 labeling index (LI) 
was approximately 30% (Figure 2D). IDH1R132H staining was 
negative. The diagnosis was GBM.
Case 2
At the first intervention, the tumor showed a high density 
of GFAP- and vimentin-negative cells with round nuclei 
(Figure 2E and F). In scattered areas, there was a honeycomb 
appearance with clear halos around the nuclei. In a wide area, 
there were typical nuclear palisades, similar to those that 
were described in polar spongioblastoma, associated with a 
typical small vessel branching (Figure 2G). Many capillaries 
and small vessels showed calcification. The Ki-67/MIB-1 LI 
was 8% (Figure 2H), and IDH1R132H staining was negative. 
The diagnosis was WHO grade II oligodendroglioma.
At the second intervention, many GFAP-positive large 
cells of the gemistocytic type were present. Diffusely, 
there was a perivascular disposition of large cells that sent 
thick processes on the vessel walls with no fibrillary aspect 
(Figure 2I–K). The aspect of the tumor was found to be 
disrupted, with dissociation areas, polymorphic nuclei, 
evident mitoses, and a Ki-67/MIB-1 LI .20% (Figure 2L). 
Oligodendroglial features were almost absent. IDH1R132H 
staining was negative. The diagnosis was WHO grade III 
oligoastrocytoma.
Case 3
The tumor was composed of rather large, irregularly shaped, 
frequently GFAP-positive cells with polymorphic and mon-
strous nuclei. The general architecture of the tumor was 
composed of cells arranged around vessels sending large 
and thick cytoplasmic extensions to the vessel walls with no 
fibrillarity (Figure 2M–O). Vessels of various sizes showed 
thick, homogeneous, hyalinized walls, often with scanty 
endothelial hyperplasia. Large and circumscribed necroses 
were present, with or without pseupalisading. Normal and 
pathological mitoses were frequent with a Ki-67/MIB-1 LI 
.20% (Figure 2P). IDH1R132H staining was  negative. Since 
the sample for histological diagnosis was very small, the 
diagnosis was tentatively that of gemistocytic astrocytoma 
with malignant features.
Table 2 List of primary antibodies used for immunofluorescence
Antibody Source Dilution Code Manufacturer
GFaP rabbit 1:200 Z0334 Dako Denmark a/s, Glostrup, Denmark
Nestina rabbit 1:200 aB5922 eMD Millipore, Billerica, Ma, Usa
CD133/1 (aC133) Mouse 1:20 130-090-422 Miltenyi Biotec, Bergisch Gladbach, Germany
sOX2a Mouse 1:100 MaB2018 r&e systems inc., Billerica, Ma, Usa
Musashi-1 rabbit 1:200 aB5977 eMD Millipore, Billerica, Ma, Usa
resTa rabbit 1:150 iHC-00141 Bethyl Laboratories inc., Montgomery, TX, Usa
GalCa Mouse 1:100 MaB342 Chemicon, eMD Millipore, Billerica, Ma, Usa
βiii-tubulina Mouse 1:250 MaB1637 Chemicon, eMD Millipore, Billerica, Ma, Usa
Note: aHeat-induced epitope retrieval required.
Abbreviations: GalC, galactosylceramidase; GFAP, glial fibrillary acidic protein; REST, RE1-silencing transcription factor; SOX2, sex determining region Y-box 2.
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In all of the cases, CD34 was expressed, together 
with vimentin, in endothelial cells and their proliferation. 
 CD68-positive cells were irregularly scattered in all of the 
cases. Reticulin production, as revealed by the Gomori 
method, was confined to vessels.
Molecular genetics
In Case 1, a typical glioma/GBM molecular signature 
was found. By LOH analysis, a common allelic loss 
was detected on the 10q chromosome arm (D10S212 
and D10S562), whereas 9p and 17p chromosomes were 
intact. The MGMT gene (but not EMP3) displayed pro-
moter hypermethylation. Direct sequencing revealed a 
stop mutation, c.822G.A (p.Trp274*), in PTEN exon 8, 
as well as a missense mutation, specifically c.824G.A 
(p.Cys275Tyr), in TP53 exon 8 (Figure 3A and B). Each 
mutation was verified to be of somatic origin and previously 
described in gliomas or glioma cell lines in the Catalogue 
of Somatic Mutations in Cancer (COSMIC database, v 67 
release, October 2013; http://www.sanger.ac.uk/genetics/
CGP/cosmic/). The IDH1/2 and BRAF hot-spot codons 
were wild type, and EGFR gene amplification was not 
found (Table 3).
In Case 2 (first intervention), LOH on 10q (D10S212, 
D10S562, and D10S190) was the only allelic imbal-
ance identified. Direct sequencing revealed a somatic 
nucleotide sequence variation, c.209 + 1G.T, in PTEN 
intron 3, which was responsible for aberrant splic-
ing (Figure 3C). The TP53 gene and the IDH1/2 and 
BRAF hot-spot codons were wild type. The EMP3 
gene (but not MGMT) displayed promoter hyperm-
ethylation, and EGFR gene amplification was not found 
(Table 3).
In Case 3, genetic analyses revealed the absence of any 
genetic/epigenetic alterations, with the exception of MGMT 
promoter hypermethylation (Table 3).
Figure 2 immunohistochemistry.
Notes: Case 1: (A) perivascular cell arrangement; H&e, 10×; (B) necrosis and polymorphic cells; H&e, 10×; (C) GFaP-positive perivascular cells; DaB, 10×; (D) Ki-67/MiB-1 
Li; DaB, 20×. Case 2 (first intervention): (E) aspect of oligodendroglioma; H&e, 10×; (F) GFaP-negative palisades; DaB, 10×; (G) rhythms and palisades; H&e, 10×; (H) Ki-
67/MiB-1 Li; DaB, 20×. Case 2 (second intervention): (I) perivascular arrangement of astrocytic cells; H&e, 20×; (J) id, H&e; 20×; (K) GFaP-positive perivascular cells; DaB, 
20×; (L) Ki-67/MiB-1 Li; DaB, 10×. Case 3 (M) perivascular arrangement of large cells; H&e, 20×; (N) polymorphic cells and vessel hyalinization; H&e, 10×; (O) GFaP-positive 
perivascular cells; DaB, 20×; (P) Ki-67/MiB-1 Li; DaB, 20×.
Abbreviations: DaB, 3,3’-Diaminobenzidine; H&e, hematoxylin and eosin; Li, labeling index; id, perivascular arrangement of astrocytic cells.
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Cell lines
NS and AC developed in Case 1, but only AC in Case 2. After 
confocal microscopy, NS expressed stemness markers (nestin, 
CD133, SOX2, Musashi-1, and REST) (Figure 4A and B), 
whereas AC expressed differentiation antigens (GFAP, GalC, 
and βIII-tubulin) (Figure 4C and D).
Molecular genetics analysis applied to the cell lines 
showed that both NS and AC from Case 1 totally mimicked 
the tumor genotype (Figure 3A and B). In contrast, AC 
from Case 2 (first intervention) did not display any genetic/
epigenetic alterations common to the respective primary 
tumor (Figure 3C).
Discussion
The three presented cases were chosen as examples of glial 
tumors with perivascular formations that could not be rec-
ognized as radiated crowns or perivascular pseudorosettes 
of ependymoma, of which, on the other hand, other features 
Lymphocytes
Lymphocytes
Primary tumor
Primary tumor
Neurospheres Adherent cells
Adherent cells
A
B
C
Figure 3 sanger direct sequencing.
Notes: Case 1: (A) electropherograms for the stop mutation c.822G.a (p.Trp274*) in PTEN exon 8 in lymphocytes, primary tumor, neurospheres, and adherent cells; 
(B) electropherograms for the missense mutation c.824G.a (p.Cys275Tyr) in TP53 exon 8 in lymphocytes, primary tumor, neurospheres, and adherent cells. Case 2 (first 
intervention): (C) electropherograms for the splice variant c.209 + 1G.T in PTEN intron 3 in lymphocytes, primary tumor, and adherent cells.
were lacking. Perivascular cells sent thick, broad, and small 
processes on vessels. In Case 1, there was a general aspect 
of high-grade astrocytic glioma with high cell proliferation, 
circumscribed necroses, and microvascular proliferations, 
and the tumor was diagnosed as such. Perivascular arrange-
ment of cells was an additional feature, occurring diffusely 
in the tumor, which precisely recalled that of astroblastoma. 
The tumor occurred in an elderly woman and showed MRI 
features consistent with those of astroblastoma.
Case 2 was a WHO grade II oligodendroglioma at the 
first intervention, with round nuclei, honeycomb appearance 
of cells, and, limited to a single area, palisades of cells inter-
mingled with capillaries similar to that previously described 
in polar spongioblastoma.25 At the second intervention, the 
tumor phenotype was different, with reduction of the oligo-
dendroglial component and the acquisition of an astrocytic 
one. It was diagnosed as an anaplastic oligoastrocytoma. 
In the tumor, there were many GFAP-positive cells of the 
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gemistocytic type sending thick processes on the vessel walls 
without a fibrillary component. The formation recalled astro-
blastoma and not ependymoma. This finding was not diffusely 
present, but limited to the astrocytic component that appeared 
in the tumor removed at the second intervention; in this 
component, it was diffusely distributed, meaning the tumor 
fell within the narrow diagnostic criteria of astroblastoma. 
Alternatively, it could have been already present at the first 
intervention, but not removed. The occurrence of the perivas-
cular asset of tumor astrocytic cells could be interpreted as 
the consequence of a peculiar tumor cell/vessel relationship, 
possibly linked to microenvironment conditioning, as in the 
other two cases and, in general, in astroblastoma.26
Case 3 was a malignant gemistocytic tumor with a diffuse 
perivascular arrangement of the cells without both end feet 
and a fibrillary component, similar to that of astroblastoma. 
It is not clear from the literature whether the criteria for rec-
ognizing astroblastoma include the dimensions of the cells, 
whether they are broad or small. The general consensus is 
that both have been accepted. Therefore, this case also might 
fall into the category of astroblastoma.
In all three cases, the typical features (perivascular cell 
disposition and hyalinization) of astroblastoma were present; 
in the first case, these features were the only characteristics 
of the tumor, while, in the other two cases, these features 
appeared alongside other phenotypic features that are typi-
cal of astrocytic tumors. In a previous study, data for 116 
patients operated on for astroblastoma were collected from 
the literature, following inclusion criteria deduced from 62 
references.9 The patients’ clinical, surgical, and radiological 
features were defined, and two main peaks of age distribution 
were observed, due to a bimodal distribution of the tumor: 
specifically, one peak in infancy and the other one in adult 
age. Astroblastoma was, therefore, considered to be a rare 
tumor described in the literature as individual cases or as 
small collections of cases, with the criteria of astroblastic 
pseudorosettes and vascular  hyalinization.11 In review of the 
literature, it can be seen that, contrarily to the diagnosis of 
astroblastoma in the strict sense, tumors with a wider range 
of features could be accepted. Possibly, different criteria are 
used in the interpretation of the perivascular distribution of 
tumor cells.
Two of our cases were malignant gliomas, and one was 
benign, turning in malignant at recurrence. This is in line with 
recent publications,13,15,17,27,28 confirming that the nature of the 
tumor can be both benign or malignant.26 No ependymoma-
tous features were present in our cases, and, unfortunately, 
it was not possible to perform an electron microscopy study. T
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It is intriguing that, in a recently published case, microvilli 
were observed in the inter- and intracellular lumina,17 sug-
gesting a relationship with ependymoma. As a matter of fact, 
this has been previously observed and, besides tanycytes, 
ependymal astrocytes have also been hypothesized to be the 
source of the tumor29,30 without identifying the tumor as an 
ependymoma.
Data on the molecular genetics of astroblastoma are 
rare and only recently available from the literature. The 
observed aberrations include gains on the 20q chro-
mosome arm and chromosome 19, and losses on 9q, 
10, and X chromosome, which have been revealed by 
comparative genomic hybridization.27 TP53 and IDH1/2 
somatic mutations have been seen to be absent.17 The 
molecular genetic profiles showed typical alterations of 
WHO grade III–IV gliomas with LOH on 10q and wild-
type IDH1/2 and BRAF genes. PTEN and TP53 somatic 
mutations, as well as MGMT promoter hypermethylation, 
occurred in Case 1, consistently with a diagnosis of high-
grade astrocytic glioma. PTEN somatic mutations and 
EMP3 promoter hypermethylation were found in Case 2, 
whereas MGMT promoter hypermethylation was the only 
molecular alteration identified in Case 3. EGFR gene 
amplification, as well as LOH on the 9p chromosome arm, 
was not found in our three cases. The presence of EMP3 
promoter hypermethylation in Case 2 is remarkable, as 
this epigenetic alteration is typical of oligodendrogliomas, 
where it is mainly associated with the 1p/19q co-deletion.23 
As such, its occurrence in Case 2 could be in line with the 
diagnosis of oligodendroglioma at the first intervention. 
However, the lack of association with the 1p/19q co-dele-
tion in Case 2 may support the diagnosis of oligoastrocy-
toma at the second intervention. The absence of a specific 
genetic/epigenetic signature in our cases may indicate that 
our tumors either were not astroblastomas or that they do 
not support astroblastoma as a specific tumor entity. It must 
be taken into account that a genetic signature of astroblas-
toma has never been described in the literature.
In Case 1, the stemness potential was typical of a 
primary GBM, in that generation of both NS expressing 
stemness antigens and AC expressing differentiation anti-
gens occurred. In Case 2, AC only developed, denouncing 
a reduced stemness potentiality. The stemness asset of cell 
lines denounced a stemness spectrum of the tumor cells, 
which, in turn, corresponded to a spectrum of phenotypic 
malignancy. Out of the great amount of knowledge on tumor 
stem cells currently available,34–36 the interpretation of can-
cer stem cells as the expression of a functional status21,31–33 
Figure 4 Immunofluorescence.
Notes: Case 1: (A) neurospheres, Musashi-1 expression; 40×; (B) id, nestin expression; 40×; (C) adherent cells, GFaP expression; 40× (confocal microscopy). Case 2 (first 
intervention): (D) adherent cells, GFaP expression; 40×. DaPi counterstaining was used for all.
Abbreviations: DaPi, 4′,6-diamidino-2′-phenylindole dihydrochloride; id, neurospheres.
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must not be forgotten. This interpretation depends on the 
tumor microenvironments,26,37 as well as on epigenetic 
influences.31
Our conclusion is that the perivascular formations 
found in our three gliomas, not identifiable with those of 
ependymoma, may be expressions of an astroblastic trend 
of the tumors. It may indicate that astroblastoma does not 
exist as an established and unique tumor entity, or that it 
exists, but that its main feature can occasionally appear 
as a special phenotype in astrocytic gliomas. The only 
reason to discuss its existence in relation to ependymoma 
may be its possible origin from tanycytes or ependymal 
astrocytes.14
Conclusion
Astroblastoma may represent a tumor phenotype either dif-
fused in the entire tumor mass or only focally represented. 
It is exclusive of astrocytic gliomas, independently of the 
histopathologic features that they can show. The perivascular 
cell distribution should be conceived as the expression of the 
molecular machinery regulated by the tumor genetics and 
epigenetics, id, microenvironment.
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